Business Recorder•3 Nov 2026, 5:12 AM PKT
•1 min read
Pakistan’s listed drugmakers earned Rs11.6 billion in 1QFY27, an 11 percent increase from a year earlier and 54 percent above the preceding quarter, Business Recorder reported, citing Topline Research. Revenue reached Rs98.8 billion, rising 5 percent year on year as prices and volumes supported sales. The report noted that this growth came despite the absence of Afghanistan exports, which had featured in the comparison period.
The sector’s market value fell to Rs505.2 billion, down 24 percent year on year, even as gross margin advanced to 43.7 percent from 41.9 percent. AGP posted a 64.6 percent gross margin; SEARL and HINOON followed at 57.2 percent and 57.1 percent. Finance expenses climbed 22 percent year on year to Rs1.1 billion, while the tax bill was Rs7.1 billion. Analysts expect volumes to benefit from new products, seasonal winter demand and a low comparison base.
At a glance
- Listed pharmaceutical companies reported Rs11.6 billion in quarterly profits.
- Sector revenue increased to Rs98.8 billion in 1QFY27.
Originally reported by Business Recorder
This page is Investify’s own summary. The full report, with all details and context, is on the publisher’s site.
Want the full article here?
Investify summarizes Pakistan Stock Exchange news in its own words and links each story to its original publisher. We always credit thee making financial decisions
More PSX market news
- Indian shares set to extend advance on softer oil, steady earningsBR• 3 Nov 2026
- Dollar under pressure as oil prices slump, Australia rate decision awaitedBR• 3 Nov 2026
- Indian rupee to benefit from oil plunge while facing technical resistance, dollar strengthBR• 3 Nov 2026
- Govt plans tax breaks for mining investors under National Mineral Policy: reportProfit• 3 Nov 2026
- Asian stocks retreat ahead of US midterms, oil steadiesBR• 3 Nov 2026
- Govt considers tokenising Pakistan’s Eurobond debt as digital asset framework takes shapeProfit• 3 Nov 2026
